Spyre Therapeutics, Inc. (SYRE) stock
SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
$101.46+7.65 (+8.15%)
Close on Nov 18, 2026Market cap $8.95BP/E –Yield –
Spyre Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Spyre Therapeutics's price to book ratio was 8.5× on Nov 11, 2026, against 4.0× a year earlier. Over the last 5 years it ranged from 0.2× to 11.6×, with a median of 3.0×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 8.5× | +4.2 |
| 2025 | Dec 31, 2025 | 4.4× | +0.7 |
| 2024 | Dec 31, 2024 | 3.7× | +2.6 |
| 2023 | Jul 31, 2023 | 1.1× | +0.7 |
| 2022 | Dec 30, 2022 | 0.4× | −1.9 |
| 2021 | Dec 31, 2021 | 2.3× | −0.3 |
| 2020 | Dec 31, 2020 | 2.6× | −0.2 |
| 2019 | Dec 31, 2019 | 2.8× | +0.2 |
| 2018 | Dec 31, 2018 | 2.6× | +1.0 |
| 2017 | Dec 29, 2017 | 1.6× | +0.7 |
| 2016 | Dec 30, 2016 | 0.9× | – |
See a number that looks wrong?